SLNO

Soleno Therapeutics (SLNO)

About Soleno Therapeutics (SLNO)

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Details

Daily high

$50.23

Daily low

$48.44

Price at open

$49.42

52 Week High

$60.92

52 Week Low

$36.61

Market cap

2.3B

Dividend yield

0.00%

Volume

521,135

Avg. volume

580,997

P/E ratio

-11.58

Soleno Therapeutics News